ArticleLa Radiologia medica2025
RegGAN-based contrast-free CT enhances esophageal cancer assessment: multicenter validation of automated tumor segmentation and T-staging.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aimed to develop a deep learning (DL) framework using registration-guided generative adversarial networks (RegGAN) to synthesize contrast-enhanced CT (Syn-CECT) from non-contrast CT (NCCT), enabling iodine-free esophageal cancer (EC) T-staging.
methodsA retrospective multicenter analysis included 1,092 EC patients (2013-2024) divided into training (N = 313), internal (N = 117), and external test cohorts (N = 116 and N = 546). RegGAN synthesized Syn-CECT by integrating registration and adversarial training to address NCCT-CECT misalignment. Tumor segmentation used CSSNet with hierarchical feature fusion, while T-staging employed a dual-path DL model combining radiomic features (from NCCT/Syn-CECT) and Vision Transformer-derived deep features. Performance was validated via quantitative metrics (NMAE, PSNR, SSIM), Dice scores, AUC, and reader studies comparing six clinicians with/without model assistance.
resultsRegGAN achieved Syn-CECT quality comparable to real CECT (NMAE = 0.1903, SSIM = 0.7723; visual scores: p ≥ 0.12). CSSNet produced accurate tumor segmentation (Dice = 0.89, 95% HD = 2.27 in external tests). The DL staging model outperformed machine learning (AUC = 0.7893-0.8360 vs. ≤ 0.8323), surpassing early-career clinicians (AUC = 0.641-0.757) and matching experts (AUC = 0.840). Syn-CECT-assisted clinicians improved diagnostic accuracy (AUC increase: ~ 0.1, p < 0.01), with decision curve analysis confirming clinical utility at > 35% risk threshold.
conclusionsThe RegGAN-based framework eliminates contrast agents while maintaining diagnostic accuracy for EC segmentation (Dice > 0.88) and T-staging (AUC > 0.78). It offers a safe, cost-effective alternative for patients with iodine allergies or renal impairment and enhances diagnostic consistency across clinician experience levels. This approach addresses limitations of invasive staging and repeated contrast exposure, demonstrating transformative potential for resource-limited settings.
Indexed as
Identifiers
40892332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.